X

Drug Profile

Research programme - retinal disease therapeutics - Bausch & Lomb/City Therapeutics

Latest Information Update: 29 Jan 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator City Therapeutics
Class Eye disorder therapies; Small interfering RNA
Mechanism of Action Protein expression modulators; RNA interference

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Research Retinal disorders

Most Recent Events

10 Jan 2025 City Therapeutics enters into a strategic collaboration with Bausch & Lomb for development of a novel therapy for retinal diseases
10 Jan 2025 Early research in Retinal disorders in USA (Intravitreous)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com